Improving clinic attendance and adherence to antiretroviral therapy through a treatment supporter intervention in Uganda: A randomized controlled trial

AIDS and Behavior

Volumn 15, Issue 8, 2011, Pages 1795-1802

  Kunutsor, Setor ^a,d   Walley, John ^a   Katabira, Elly ^b   Muchuro, Simon ^b   Balidawa, Hudson ^c   Namagala, Elizabeth ^c   Ikoona, Eric ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b MAKERERE UNIVERSITY   (Uganda)

^c Uganda National AIDS Control Programme   (Uganda)

^d MALARIA CONSORTIUM   (United Kingdom)

Author keywords

Adherence; Anti retroviral therapy; Clinic attendance; HIV AIDS; Treatment supporter

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AMBULATORY CARE; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERVENTION STUDY; MALE; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; SOCIAL SUPPORT; STATISTICS; TREATMENT OUTCOME; UGANDA; UTILIZATION REVIEW; VIROLOGY; VIRUS LOAD;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV-1; HUMANS; INTERVENTION STUDIES; MALE; OFFICE VISITS; PATIENT COMPLIANCE; SOCIAL SUPPORT; TREATMENT OUTCOME; UGANDA; VIRAL LOAD;

EID: 84555219965     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-011-9927-9     Document Type: Article

References (39)

1. UNAIDS 2009 Report on the Global AIDS Epidemic. 2009. http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/2009/ default.asp. Accessed 25 Mar 2010.
2. Uganda AIDS Commission, National HIV & AIDS Stakeholders & Services Mapping Report, June 2009. http://data.unaids.org/pub/Report/2010/ uganda-2010-country-progress-report-en.pdf. Accessed 12 Oct 2010.
3. Uganda AIDS Commission. National Strategic Framework for HIV/AIDS. 2008. http://www.aidsuganda.org/. Accessed 25 Mar 2010.
4. Taiwo B. Adherence to antiretroviral therapy: The more you look, the more you see. Curr Opin HIV AIDS. 2009;4(6):488-92.
5. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-3. (Pubitemid 32549871)
6. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: Comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33:1417-23. (Pubitemid 32955198)
7. Paterson DL, Swindells S, Mohr J. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30. (Pubitemid 30432540)
8. Turner BJ. Adherence to antiretroviral therapy by HIV-infected patients. J Infect Dis. 2002;185(S2):S143-51. (Pubitemid 34499451)
9. Koenig SP, Leandre F, Farmer PE. Scaling-up HIV treatment programmes in resource-limited settings: The rural Haiti experience. AIDS. 2004;18(3):S21-5. (Pubitemid 39037455)
10. Laurent C, Diakhateo N, Fatou Ngom Gueye N, et al. The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS. 2002;16(10): 1363-70. (Pubitemid 34722068)
11. Orrell C, Bangsberg D, Badri M, Wood R. Adherence is not a barrier to delivery of HIV antiretroviral therapy in resource-poor countries. AIDS. 2003;17:1369-75. (Pubitemid 36819851)
12. Birbeck GL, Chomba E, Kvalsund M, et al. Antiretroviral adherence in rural Zambia: The first year of treatment availability. Am J Trop Med Hyg. 2009;80(4):669-74.
13. Escott S, Walley J. Listening to those on the frontline: Lessons for community-based tuberculosis programmes from a qualitative study in Swaziland. Soc Sci Med. 2005;61(8):1701-10. (Pubitemid 40982162)
14. Wright J, Walley J, Philip A, et al. Direct observation of treatment for tuberculosis: A randomized controlled trial of community health workers versus family members. Trop Med Int Health. 2004;9(5):559-65. (Pubitemid 38657280)
15. Max B, Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin Infect Dis. 2000;30(Suppl 2):S96-116.
16. Taiwo BO, Idoko JA, Welty LJ, et al. Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2009;50:176-81.
17. Nachega JB, Chaisson RE, Goliath R, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010;24(9):1273-80.
18. WHO IMAI/IMCI Publications. http://www.who.int/hiv/pub/imai/en/index. html. Accessed 11 May 2010.
19. Kunutsor S, Evans M, Thoulass J, et al. Ascertaining baseline levels of antiretroviral therapy adherence in Uganda: A multimethod approach. J Acquir Immune Defic Syndr. 2010;55(2): 221-4.
20. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968-77. (Pubitemid 32466236)
21. Chalker J, Andualem T, Tadeg H, et al. Developing standard methods to monitor adherence to antiretroviral medicines and treatment defaulting in resource-poor settings. The International Network for the Rational Use of Drugs Initiative on Adherence to Antiretroviral Therapy. EssentMedMonit. 2009;(1):4-8. Available at http://www.who.int/medicines/publications/monitor/EMM-art3 Issue-1-2009.pdf. Accessed 11 May 2010.
22. Calmy A, Pinoges L, Szumilin E, et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: Multicentre observational cohort. AIDS. 2006;20(8):1163-9. (Pubitemid 43786105)
23. Ferradini L, Jeanin A, Pinoges L, et al. Scaling up of highly active antiretroviral therapy in a rural district of Malawi: An effective assessment. Lancet. 2006;367(9519):1335-42.
24. Nachega JB, Knowlton AR, Deluca A, et al. Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006; 43(Suppl 1):S127-33. (Pubitemid 44885652)
25. Oyugi J, Byakika-Tusiime JB, Charlebois ED, et al. Multple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-2. (Pubitemid 38989377)
26. Weiser S, Wolfe W, Bangsberg D, et al. Barriers to antiretroviral adherence for patients living with HIV and AIDS in Botswana. J Acquir Immune Defic Syndr. 2003;34(3):282-8.
27. Nachega JB, Stein DM, Lehman DA, et al. Adherence to antiretroviral therapy in HIV-infected adults in Soweto, South Africa. AIDS Res Hum Retroviruses. 2004;20(10):1053-6. (Pubitemid 39392009)
28. Crane JT, Kawuma A, Oyugi JH, et al. The price of adherence: Qualitative findings from HIV positive individuals purchasing fixed-dose combination generic HIV antiretroviral therapy in Kampala, Uganda. AIDS. 2006;10:437-42. (Pubitemid 44174972)
29. Degefa A, Sanders EJ, Mekonnen Y, et al. Knowledge and attitudes towards antiretroviral therapy among factory workers participating in a cohort on HIV and AIDS, Addis Ababa, Ethiopia. Ethiop Med J. 2003;41(Suppl 1):75-87.
30. Norman A, Chopra M, Kadiyala S. Factors related to HIV disclosure in 2 South African communities. Am J Public Health. 2007;97:1775-81. (Pubitemid 351182284)
31. Charurat M, Oyegunle M, Benjamin R, et al. Patient retention and adherence to antiretrovirals in a large antiretroviral therapy program in Nigeria: A longitudinal analysis for risk factors. PLoS One. 2010;5(5):e10584.
32. Ramadhani HO, Thielman NM, Landman KZ, et al. Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. Clin Infect Dis. 2007;45:1492-8. (Pubitemid 351411882)
33. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr. 2006;43(1):78-84. (Pubitemid 44306492)
34. Uzochukwu BSC, Onwujekwe OE, Onoka AC, et al. Determinants of non-adherence to subsidized anti-retroviral treatment in southeast Nigeria. Health Policy Plan. 2009;24:189-96.
35. Ammassari A, Trotta MP, Murri R, et al. Correlates and predictors of adherence to highly active antiretroviral therapy: Overview of published literature. J Acquir Immune Defic Syndr. 2002; 31(3):S123-7. (Pubitemid 35453571)
36. Haynes RB. Determinants of compliance: The disease and the mechanics of treatment. In: Haynes RB, Sackett DL, editors. Compliance in health care. Baltimore: Johns Hopkins University Press; 1979. p. 49-62.
37. Horne R. Adherence to medication, a review of existing research. In: Myers L, Midence K, editors. Adherence to treatment in medical conditions. London: Harwood Academic; 1998. p. 285-310.
38. Zachariah R, Harries AD, Ishikawa N, et al. Operational research in low-income countries: What, why, and how? Lancet Infect Dis. 2009;9:711-7.
39. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis. 2002;34:1115-21. (Pubitemid 34289685)